

File 5: Biosis Previews(R) 1969-2004/May W5

(c) 2004 BIOSIS

File 73: EMBASE 1974-2004/May W5

(c) 2004 Elsevier Science B.V.

File 155: MEDLINE(R) 1966-2004/May W5

(c) format only 2004 The Dialog Corp.

\*File 155: Medline has been reloaded. Accession numbers have changed. Please see HELP NEWS 154 for details.

File 399: CA SEARCH(R) 1967-2004/UD=14024

(c) 2004 American Chemical Society

\*File 399: Use is subject to the terms of your user/customer agreement. Alert feature enhanced for multiple files, etc. See HELP ALERT.

Set Items Description

--- -----

? e au=lin rong-hwa ?

Ref	Items	Index-term
E1	3	AU=LIN RONG-HUA
E2	30	AU=LIN RONG-HWA
E3	0	*AU=LIN RONG-HWA ?
E4	1	AU=LIN RONG-JING
E5	8	AU=LIN RONG-JYH
E6	1	AU=LIN RONG-LUH
E7	1	AU=LIN RONG-SHINN
E8	2	AU=LIN RONG-XI
E9	2	AU=LIN RONGBIAO
E10	1	AU=LIN RONGCHEN
E11	2	AU=LIN RONGFU
E12	1	AU=LIN RONGGEN

Enter P or PAGE for more

? s e1-e3

3 AU=LIN RONG-HUA  
30 AU=LIN RONG-HWA  
0 AU=LIN RONG-HWA ?

S1 33 E1-E3

? e au=wu chung-hsiun ?

Ref	Items	Index-term
E1	6	AU=WU CHUNG-HSING
E2	2	AU=WU CHUNG-HSIUN
E3	0	*AU=WU CHUNG-HSIUN ?
E4	2	AU=WU CHUNG-HSIUN H
E5	3	AU=WU CHUNG-HSIUN HERBERT
E6	1	AU=WU CHUNG-HSIUN HEREBERT
E7	5	AU=WU CHUNG-HSUN
E8	62	AU=WU CHUNG-I
E9	5	AU=WU CHUNG-JUNG
E10	1	AU=WU CHUNG-LIN
E11	12	AU=WU CHUNG-MAY
E12	1	AU=WU CHUNG-MING

Enter P or PAGE for more

? s e2-e7

2 AU=WU CHUNG-HSIUN  
0 AU=WU CHUNG-HSIUN ?  
2 AU=WU CHUNG-HSIUN H  
3 AU=WU CHUNG-HSIUN HERBERT  
1 AU=WU CHUNG-HSIUN HEREBERT  
5 AU=WU CHUNG-HSUN

S2 13 E2-E7

? e au=hsu pei-ling ?

Ref	Items	Index-term
E1	0	*AU=HSU PEI-LING ?
E2	1	AU=HSU PEI-SHUANG
E3	2	AU=HSU PEI-YU
E4	6	AU=HSU PEI-YUNG
E5	1	AU=HSU PEIHONG
E6	1	AU=HSU PENG-LIN
E7	2	AU=HSU PENG-WEI
E8	1	AU=HSU PETER C
E9	1	AU=HSU PHILIP
E10	2	AU=HSU PHILLIP
E11	1	AU=HSU PI-CHANG
E12	5	AU=HSU PI-CHEN

Enter P or PAGE for more

? s s(1 or s2) and (psgl?)

0 S(1

13 S2)

1291 PSGL?

S3 0 S(1 OR S2) AND (PSGL?)

? s (psgl? or p(w)selectin(W)glycoprotein(W)ligand) and (diabetes

>>>Unmatched parentheses

? s (psgl? or p(w)selectin(W)glycoprotein(W)ligand) and (diabetes)

1291 PSGL?

4542066 P

33878 SELECTIN

291626 GLYCOPROTEIN

384590 LIGAND

1323 P(W) SELECTIN(W) GLYCOPROTEIN(W) LIGAND

589096 DIABETES

S4 15 (PSGL? OR P(W) SELECTIN(W) GLYCOPROTEIN(W) LIGAND) AND  
(DIABETES)

? rd s4

...completed examining records

S5 10 RD S4 (unique items)

? t s5/7/all

5/7/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0014384123 BIOSIS NO.: 200300340866

Protein kinase C beta2-dependent phosphorylation of core 2 GlcNAc-T

promotes leukocyte-endothelial cell adhesion: A mechanism underlying

capillary occlusion in diabetic retinopathy.

AUTHOR: Chibber Rakesh (Reprint); Ben-Mahmud Bahaedin M; Mann Giovanni E;

Zhang Jin J; Kohner Eva M

AUTHOR ADDRESS: Centre for Cardiovascular Biology and Medicine, GKT School

of Biomedical Sciences, King's College London, 2nd Floor, New Hunt's

House, London, SE1 1UL, UK\*\*UK

AUTHOR E-MAIL ADDRESS: rakesh.chibber@kcl.ac.uk

JOURNAL: Diabetes 52 (6): p1519-1527 June 2003 2003

MEDIUM: print

ISSN: 0012-1797 \_(ISSN print)

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Increased leukocyte-endothelial cell adhesion is a key early event in the development of retinopathy and atherogenesis in diabetic patients. We recently reported that raised activity of glycosylating enzyme (beta)11,6 acetylglucosaminyltransferase (core 2 GlcNAc-T) is responsible for increased leukocyte-endothelial cell adhesion and capillary occlusion in retinopathy. Here, we demonstrate that elevated

glucose increases the activity of core 2 GlcNAc-T and adhesion of human leukocytes to retinal capillary endothelial cells, in a dose-dependent manner, through **diabetes**-activated serine/threonine protein kinase C beta2 (PKCbeta2)-dependent phosphorylation. This regulatory mechanism, involving phosphorylation of core 2 GlcNAc-T, is also present in polymorphonuclear leukocytes isolated from type 1 and type 2 diabetic patients. Inhibition of PKCbeta2 activation with the specific inhibitor, LY379196, attenuated serine phosphorylation of core 2 GlcNAc-T and prevented increased leukocyte-endothelial cell adhesion. Raised activity of core 2 GlcNAc-T was associated with a threefold increase in O-linked glycosylation of **P-selectin glycoprotein ligand-1** on the surface of leukocytes of diabetic patients compared with age-matched control subjects. PKCbeta2-dependent phosphorylation of core 2 GlcNAc-T may thus represent a novel regulatory mechanism for activation of this key enzyme in mediating increased leukocyte-endothelial cell adhesion and capillary occlusion in diabetic retinopathy.

5/7/2 (Item 2 from file: 5)  
DIALOG(R) File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0013998538 BIOSIS NO.: 200200592049

Administration of recombinant **P-selectin glycoprotein**

**ligand** Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model

AUTHOR: Zhou Zhongmin; Penn Marc S; Forudi Farhad; Zhou Xiaorong; Tarakji Khaldoun; Topol Eric J; Lincoff A Michael; Wang Kai (Reprint)

AUTHOR ADDRESS: Department of Cardiology, Cleveland Clinic Foundation, 9500 Euclid Ave, F25, Cleveland, OH, 44195, USA\*\*USA

JOURNAL: Arteriosclerosis Thrombosis and Vascular Biology 22 (10): p 1598-1603 October, 2002 2002

MEDIUM: print

ISSN: 1079-5642

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Objective: P-selectin-mediated leukocyte-endothelium and leukocyte-platelet interaction has been reported after vascular injury and has been correlated with neointimal hyperplasia, but its role in neointimal formation after arterial injury in **diabetes** has not been described. Methods and Results: Using a Zucker diabetic rat balloon injury model, we examined the role of P-selectin in the vascular inflammatory process and neointimal formation after balloon injury. Immunohistochemistry revealed that P-selectin was intensely expressed and that CD45-positive leukocyte infiltration was significantly increased after arterial injury. A single preprocedural intravenous administration of a recombinant P-selectin-soluble glycoprotein ligand-Ig inhibited CD45-positive leukocyte accumulation and suppressed neointimal formation in the Zucker diabetic rat model. Conclusions: These results suggest that reduction of P-selectin-mediated leukocyte activation with the use of recombinant P-selectin-soluble glycoprotein ligand-Ig decreases the inflammatory response and limits neointimal formation after balloon injury in **\*\*\*diabetes\*\*\*** .

5/7/3 (Item 3 from file: 5)  
DIALOG(R) File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0013814769 BIOSIS NO.: 200200408280

P-selectin neutralization prevents neointimal formation in a diabetic rat model

AUTHOR: Zhou Zhongmin (Reprint); Wang Kai (Reprint); Forudi Farhad  
(Reprint); Zhou Xiaorong (Reprint); Tarakji Khaldoun (Reprint); Penn Marc  
S (Reprint); Lincoff A Michael (Reprint)  
AUTHOR ADDRESS: The Cleveland Clinic Foundation, Cleveland, OH, USA\*\*USA  
JOURNAL: Journal of the American College of Cardiology 39 (5 Supplement A  
) : p53A March 6, 2002 2002  
MEDIUM: print  
CONFERENCE/MEETING: 51st Annual Scientific Session of the American College  
of Cardiology Atlanta, GA, USA March 17-20, 2002; 20020317  
ISSN: 0735-1097  
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster  
RECORD TYPE: Citation  
LANGUAGE: English

5/7/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0013681707 BIOSIS NO.: 200200275218  
Platelet-leukocyte conjugates are increased in diabetic women compared to  
diabetic men with cardiovascular disease  
AUTHOR: Tuttle Hillary (Reprint); Davis-Gorman Grace (Reprint); Copeland  
Jack (Reprint); McDonagh Paul (Reprint); Goldman Steve  
AUTHOR ADDRESS: Univ of Arizona, Tucson, AZ, USA\*\*USA  
JOURNAL: Circulation 104 (17 Supplement): pII.320 October 23, 2001 2001  
MEDIUM: print  
CONFERENCE/MEETING: Scientific Sessions 2001 of the American Heart  
Association Anaheim, California, USA November 11-14, 2001; 20011111  
SPONSOR: American Heart Association  
ISSN: 0009-7322  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Citation  
LANGUAGE: English

5/7/5 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2004 Elsevier Science B.V. All rts. reserv.

11454873 EMBASE No: 2002026373  
Differential regulation of mouse kidney sodium-dependent transporters  
mRNA by cadmium  
Tabatabai N.M.; Blumenthal S.S.; Lewand D.L.; Petering D.H.  
S.S. Blumenthal, Department of Medicine, Medical College of Wisconsin,  
Zablocki Veterans Admin. Med. Center, 5000 West National Avenue,  
Milwaukee, WI 53295 United States  
AUTHOR EMAIL: ssblumen@mcw.edu  
Toxicology and Applied Pharmacology ( TOXICOL. APPL. PHARMACOL. ) (United  
States) 15 DEC 2001, 177/3 (163-173)  
CODEN: TXAPA ISSN: 0041-008X  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 30

Chronic exposure to cadmium can result in renal glycosuria. Previously,  
we reported that cadmium reduced the relative abundance of the  
sodium-glucose cotransporter mRNA (Blumenthal et al., Toxicol. Appl.  
Pharmacol. 149, 49-54, 1998). To investigate this phenomenon further, we  
isolated full-length cDNA clones encoding both high- and low-affinity  
sodium-dependent glucose transporters SGLT1 and SGLT2, respectively, from  
cultured mouse kidney cortical cells. We also amplified a fragment of  
another putative sodium-glucose cotransporter with homology to the known  
SAAT1/ \*\*\*pSGLT2\*\*\* or SGLT3 from our cultured cells and named it SGLT3. In

order to examine the effect of cadmium on these transporters, primary cultures of mouse kidney cortical cells were exposed to micromolar concentrations of cadmium for 24 h and levels of SGLT1, SGLT2, and SGLT3 mRNA were determined by semiquantitative RT-PCR. Five to 10  $\mu$ M of cadmium inhibited sodium-dependent uptake of the glucose analog, alpha-methyl D-glucopyranoside and progressively reduced the level of SGLT1. Cadmium also inhibited SGLT2 mRNA by 37%, but no further decline was observed at concentrations of cadmium greater than 5  $\mu$ M. While cadmium inhibited SGLT1 and SGLT2, it significantly stimulated the expression of SGLT3 by fivefold. These results imply that individual sodium-glucose cotransporter mRNA species are not regulated in a similar fashion. In addition, the isolation of three separate SGLT species from these cultures suggests that, in addition to SGLT1 and SGLT2, glucose reabsorption by renal epithelial cells might involve additional glucose transporters such as SGLT3. (c) 2001 Elsevier Science.

5/7/6 (Item 1 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2004 American Chemical Society. All rts. reserv.

139035100 CA: 139(3)35100y PATENT  
Methods and compositions for modulating interleukin-21 (IL-21) or IL-21 receptor (IL-21R) activity and therapeutic uses  
INVENTOR(AUTHOR): Carter, Laura; Carreno, Beatriz; Lowe, Leslie D.; Whitters, Matthew J.; Dunussi, Kyri; Collins, Mary; Ma, Margery; Young, Deborah A.; Witek, Joann S.; Larsen, Glenn; Kasaian, Marion T.; Donaldson, Debra D.; Unger, Michelle  
LOCATION: USA  
ASSIGNEE: Wyeth, John, and Brother Ltd.  
PATENT: U.S. Pat. Appl. Publ. ; US 20030108549 A1 DATE: 20030612  
APPLICATION: US 264634 (20021004) \*US 40005 (19980317) \*US 560766 (20000428) \*US 569384 (20000511) \*US 972218 (20011004) \*US PV373746 (20020417)  
PAGES: 109 pp., Cont.-in-part of U.S. Ser. No. 972,218. CODEN: USXXCO  
LANGUAGE: English CLASS: 424145100; A61K-039/395A; A61K-031/525B; A61K-031/4745B; A61K-031/415B  
SECTION:  
CA215005 Immunochemistry  
CA201XXX Pharmacology  
CA203XXX Biochemical Genetics  
CA263XXX Pharmaceuticals  
IDENTIFIERS: interleukin 21 receptor agonist antagonist immunosuppressant immunostimulant, autoimmune disease cancer infection soluble IL21 receptor agonist antagonist  
DESCRIPTORS:  
Immunostimulants...  
adjuvants; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
Interleukin 12... Interleukin 15... Interleukin 17... Interleukin 18...  
Tumor necrosis factors...  
agonists and antagonists; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
Spinal column,disease...  
ankylosing spondylitis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
Antibodies...  
anti-IL-21R; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
CD22 (antigen)... CD4 (antigen)...

- antibodies; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Cytotoxic agents...
  - antimetabolites; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Dermatitis...
  - atopic; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Thyroid gland,disease...
  - autoimmune thyroiditis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Estrogen receptors...
  - $\beta$  agonist; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Drug delivery systems...
  - carriers; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Intestine,disease...
  - Crohn's; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- B cell(lymphocyte)...
  - depletion; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Lymphocyte...
  - effector cell; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Protein motifs...
  - extracellular domain; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- cDNA sequences...
  - for IL-21 receptor from human and mouse; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Immunoglobulins...
  - fragments, anti-IL-21R; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Immunoglobulins...
  - fragments; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Antibodies...
  - fusion products; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Immunoglobulins...
  - G; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Immunoglobulins...
  - G1; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Immunoglobulins...
  - G2; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Antibodies...
  - humanized; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and

infections

Mouse...  
 IL-21R/MU-1 from; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Disease, animal...  
 immune cell-assocd.; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Drug delivery systems...  
 immunoconjugates; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Neoplasm...  
 immunotherapy; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Drug delivery systems...  
 immunotoxins; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Parasite...  
 infection by; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Intestine, disease...  
 inflammatory; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Cytokines... Enzymes, biological studies...  
 inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Diabetes mellitus...  
 insulin-dependent; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Interleukin receptors...  
 interleukin-21, MU-1; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunotherapy... Autoimmune disease... Molecular cloning... Antitumor agents... Antimicrobial agents... Drug delivery systems... Allergy...  
 Animal tissue culture... Anti-inflammatory agents... Arthritis... Asthma...  
 B cell(lymphocyte)... CD4-positive T cell... CD8-positive T cell...  
 Cytotoxic agents... DNA sequences... Dermatitis... Drugs... Eczema...  
 Genetic vectors... Human... Immunostimulants... Immunosuppressants...  
 Leukemia... Lymphocyte... Lymphoma... Macrophage... Megakaryocyte...  
 Multiple sclerosis... Myasthenia gravis... Osteoarthritis... Protein sequences... Psoriasis... Rheumatoid arthritis... T cell(lymphocyte)...  
 Transplant rejection... Vaccines... Fusion proteins(chimeric proteins)...  
 Growth inhibitors, animal... Immunoglobulin receptors... Immunoglobulins...  
 Radionuclides, biological studies... Toxins...  
 interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Rheumatoid arthritis...  
 juvenile; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

T cell(lymphocyte)...  
 memory; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Antibodies...  
 monoclonal; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and

infections  
Lymphocyte...  
natural killer cell; interleukin-21 receptor agonists and antagonists  
for treating transplant rejection, autoimmune diseases, cancers and  
infections  
Antibodies...  
neutralizing; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections  
Transcription factors...  
NF- $\kappa$ B (nuclear factor of  $\kappa$  light chain gene enhancer in  
B-cells), inhibitors; interleukin-21 receptor agonists and antagonists  
for treating transplant rejection, autoimmune diseases, cancer  
Anti-inflammatory agents...  
nonsteroidal; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections  
Selectins...  
P-, inhibitors; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections  
Glycoproteins...  
PSGL-1 (P-selectin glycoprotein ligand-1), inhibitors; interleukin-21  
receptor agonists and antagonists for treating transplant rejection,  
autoimmune diseases, cancers and infections  
Arthritis...  
psoriatic arthritis; interleukin-21 receptor agonists and antagonists  
for treating transplant rejection, autoimmune diseases, cancers and  
infections  
Proteins...  
p38, inhibitors; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections  
Tumor necrosis factor receptors...  
p55 and p75; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections  
Connective tissue,disease...  
scleroderma; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections  
Molecules...  
small; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections  
Animal tissue,disease...  
soft, neoplasm; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections  
Neoplasm...  
solid; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections  
Lupus erythematosus...  
systemic; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections  
Infection...  
therapy; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections  
Vaccines...  
tumor; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections  
Antigens...  
tumor-assocd.; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections



Antigens...

tumor-assocd., RAGE; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Antitumor agents...

vaccines; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Blood vessel,disease...

vasculitis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Infection...

viral; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

CAS REGISTRY NUMBERS:

542817-54-9P 542817-58-3P amino acid sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
9001-84-7 329900-75-6 inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
140281-74-9 59-05-2 53123-88-9 75706-12-6 83869-56-1 162635-04-3 interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
542817-53-8P nucleotide sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
542817-52-7DP 542817-56-1DP subfragments are claimed, amino acid sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
542817-51-6DP 542817-55-0DP 542817-57-2DP subfragments are claimed, nucleotide sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
542820-51-9 542820-52-0 542820-53-1 542820-55-3 542820-56-4 542820-57-5 542820-58-6 542820-59-7 542820-60-0 542820-62-2 542820-64-4 542820-66-6 542820-68-8 542820-70-2 542820-72-4 542820-74-6 542820-76-8 542820-78-0 542820-79-1 542820-80-4 unclaimed nucleotide sequence; methods and compns. for modulating interleukin-21 (IL-21) or IL-21 receptor (IL-21R) activity and therapeutic uses  
542820-50-8 542820-54-2 542820-61-1 542820-63-3 542820-65-5 542820-67-7 542820-69-9 542820-71-3 542820-73-5 542820-75-7 542820-77-9 unclaimed protein sequence; methods and compns. for modulating interleukin-21 (IL-21) or IL-21 receptor (IL-21R) activity and therapeutic uses  
510729-85-8 434283-61-1 219312-69-3 138831-86-4 unclaimed sequence; methods and compns. for modulating interleukin-21 (IL-21) or IL-21 receptor (IL-21R) activity and therapeutic uses

5/7/7 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

138302654 CA: 138(20)302654p PATENT

Interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

INVENTOR(AUTHOR): Carter, Laura; Whitters, Matthew J.; Collins, Mary; Young, Deborah A.; Larsen, Glenn; Donaldson, Debra D.; Lowe, Leslie D.; Dunussi, Kyri; Ma, Margery; Witek, Joann S.; Kasaian, Marion T.; Ungar, Michelle

LOCATION: USA

ASSIGNEE: Wyeth, John, and Brother Ltd.

PATENT: PCT International ; WO 200328630 A2 DATE: 20030410  
APPLICATION: WO 2002US29839 (20021004) \*US 972218 (20011004) \*US PV373746  
(20020417)

PAGES: 176 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;  
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM;  
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS  
; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE;  
ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI;  
CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA215005 Immunochemistry

CA201XXX Pharmacology

CA203XXX Biochemical Genetics

CA263XXX Pharmaceuticals

IDENTIFIERS: interleukin 21 receptor agonist antagonist immunosuppressant  
immunostimulant transplant rejection, autoimmune disease cancer infection  
soluble IL21 receptor agonist antagonist

DESCRIPTORS:

Immunostimulants...

adjuvants; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections

Tumor necrosis factors... Interleukin 12... Interleukin 15... Interleukin  
17... Interleukin 18...

agonists and antagonists; interleukin-21 receptor agonists and  
antagonists for treating transplant rejection, autoimmune diseases,  
cancers and infections

Spinal column,disease...

ankylosing spondylitis; interleukin-21 receptor agonists and  
antagonists for treating transplant rejection, autoimmune diseases,  
cancers and infections

CD4(antigen)... CD22(antigen)...

antibodies; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections

Cytotoxic agents...

antimetabolites; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections

Dermatitis...

atopic; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections

Thyroid gland,disease...

autoimmune thyroiditis; interleukin-21 receptor agonists and  
antagonists for treating transplant rejection, autoimmune diseases,  
cancers and infections

Immunoglobulins...

A1; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...

A2; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections

Infection...

bacterial; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections

Estrogen receptors...

$\beta$  agonist; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections

Drug delivery systems...  
carriers; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections

Antibodies...  
chimeric; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections

Intestine,disease...  
Crohn's; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...  
D; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections

B cell(lymphocyte)...  
depletion; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections

Immunoglobulins...  
E; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections

Lymphocyte...  
effector cell; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections

Protein motifs...  
extracellular domain; interleukin-21 receptor agonists and antagonists  
for treating transplant rejection, autoimmune diseases, cancers and  
infections

Immunoglobulins...  
fragments; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections

Immunoglobulins...  
G; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...  
G1; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...  
G2; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...  
G2a; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...  
G3; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...  
G4; interleukin-21 receptor agonists and antagonists for treating  
transplant rejection, autoimmune diseases, cancers and infections

Antibodies...  
humanized; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections

Disease,animal...  
immune cell-assocd.; interleukin-21 receptor agonists and antagonists  
for treating transplant rejection, autoimmune diseases, cancers and  
infections

Drug delivery systems...  
immunoconjugates; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and  
infections

Drug delivery systems...  
immunotoxins; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and

- infections
- Intestine,disease...
  - inflammatory; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Cytokines... Enzymes,biological studies...
  - inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Diabetes mellitus...
  - insulin-dependent; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Immunosuppressants... Lymphocyte... T cell(lymphocyte)... CD4-positive T cell... CD8-positive T cell... B cell(lymphocyte)... Macrophage... Megakaryocyte... Transplant rejection... Autoimmune disease... Antigens... Vaccines... Immunostimulants... Antitumor agents... Infection... Parasite ... Immunotherapy... Multiple sclerosis... Arthritis... Rheumatoid arthritis... Myasthenia gravis... Dermatitis... Eczema... Psoriasis... Asthma... Allergy... Antibodies... Immunoglobulins... Toxins... Radionuclides,biological studies... Lymphoma... Leukemia... Parasitic worm ... Bacterium(genus)... Drugs... Growth inhibitors,animal... Anti-inflammatory agents... Cytotoxic agents... Human... Fusion proteins(chimeric proteins)... Osteoarthritis... Mammalia... Immunoglobulin receptors... Molecular cloning... DNA sequences... Protein sequences... Protozoa... Genetic vectors... Animal tissue culture... Immunoglobulin receptors...
  - interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Rheumatoid arthritis...
  - juvenile; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Immunoglobulins...
  - M; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Honeybee...
  - mellitin signal peptide from; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- T cell(lymphocyte)...
  - memory; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Antibodies...
  - monoclonal; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Mouse... Rodentia...
  - MU-1; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Lymphocyte...
  - natural killer cell; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Antibodies...
  - neutralizing; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Transcription factors...
  - NF- $\kappa$ B (nuclear factor of  $\kappa$  light chain gene enhancer in B-cells), inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancer
- Anti-inflammatory agents...
  - nonsteroidal; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and

- infections
- Selectins...
  - P-, inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Glycoproteins...
  - PSGL-1 (P-selectin glycoprotein ligand-1), inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Arthritis...
  - psoriatic arthritis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Proteins...
  - p38, inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Tumor necrosis factor receptors...
  - p55 and p75; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Connective tissue,disease...
  - scleroderma; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Molecules...
  - small; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Animal tissue,disease...
  - soft, neoplasm; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Neoplasm...
  - solid; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Lupus erythematosus...
  - systemic; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Vaccines...
  - tumor; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Antigens...
  - tumor-assocd.; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Antigens...
  - tumor-assocd., RAGE; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Antitumor agents...
  - vaccines; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Blood vessel,disease...
  - vasculitis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Infection...
  - viral; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Interleukins... Interleukin receptors...
  - 21; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
- Interleukins...
  - 22; agonists and antagonists; interleukin-21 receptor agonists and

antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

CAS REGISTRY NUMBERS:

434283-61-1 amino acid sequence, signal peptide, included in fusion protein; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
510729-85-8 amino acid sequence, STAT docking site, STAT5; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
510788-28-0P 510787-86-7P 510788-32-6P 510788-34-8P 510788-36-0P 510788-38-2P 510788-40-6P 510788-42-8P 510788-44-0P amino acid sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
329900-75-6 9001-84-7 inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
59-05-2 75706-12-6 53123-88-9 162635-04-3 83869-56-1 185243-69-0 140281-74-9 interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
510787-85-6P 510788-27-9P 510788-31-5P 510788-33-7P 510788-35-9P 510788-37-1P 510788-39-3P 510788-41-7P 510788-43-9P nucleotide sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
510787-80-1DP 510787-84-5DP 510787-82-3DP subfragments are claimed, amino acid sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
510786-18-2DP 510787-83-4DP 510787-81-2DP subfragments are claimed, nucleotide sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
510792-63-9 510792-64-0 510792-65-1 510792-70-8 510792-71-9 510792-72-0 510792-73-1 510792-74-2 510792-75-3 510792-78-6 510792-79-7 510792-80-0 unclaimed nucleotide sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
510792-62-8 510792-66-2 510792-76-4 219312-69-3 138831-86-4 unclaimed protein sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections  
510792-81-1 510792-82-2 unclaimed sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

5/7/8 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

137179893 CA: 137(13)179893r PATENT

Methods for identifying compounds that inhibit or reduce PTP1B (protein tyrosine phosphatase 1B) expression

INVENTOR(AUTHOR): Zinker, Bradley A.; Trevillyan, James M.; Jirousek, Michael R.; Rondinone, Christina M.; Cowser, Lex M.; Wyatt, Jacqueline; Monia, Brett P.; Butler, Madeline M.; Waring, Jeffrey French

LOCATION: USA

ASSIGNEE: Abbott Laboratories; Isis Pharmaceuticals, Inc.

PATENT: PCT International ; WO 200264840 A2 DATE: 20020822

APPLICATION: WO 2002US4194 (20020213) \*US PV268399 (20010213) \*US 74194 (20020212)

PAGES: 72 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12Q-001/68A; C12N-015/11B; C12N-015/12B; C07K-014/47B; A01K-067/027B

DESIGNATED COUNTRIES: CA; JP; MX DESIGNATED REGIONAL: AT; BE; CH; CY; DE

; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR

SECTION:

CA201010 Pharmacology

IDENTIFIERS: protein tyrosine phosphatase 1B inhibitor identification,  
diabetes treatment protein tyrosine phosphatase 1B inhibitor

DESCRIPTORS:

Cyclins...

A, gene encoding, as marker; methods for identifying inhibitors of  
protein tyrosine phosphatase 1B expression in insulin resistant obese  
non-human mammals by detection of phosphatidylinositol-3-kinase

Cytokines...

adiponectin, gene encoding, as marker; methods for identifying  
inhibitors of protein tyrosine phosphatase 1B expression in insulin  
resistant obese non-human mammals by detection of phosphatidylinosito

Transport proteins...

amino acid-transporting, insulin-activated, gene encoding, as marker;  
methods for identifying inhibitors of protein tyrosine phosphatase 1B  
expression in insulin resistant obese non-human mammals by d

Polynucleotides... Phosphorothioate oligodeoxyribonucleotides...

antisense; methods for identifying inhibitors of protein tyrosine  
phosphatase 1B expression in insulin resistant obese non-human mammals  
by detection of phosphatidylinositol-3-kinase isoforms

Globins...

B, complex, gene encoding, as marker; methods for identifying  
inhibitors of protein tyrosine phosphatase 1B expression in insulin  
resistant obese non-human mammals by detection of phosphatidylinositol

Adrenoceptors...

$\beta$ 3, gene encoding, as marker; methods for identifying inhibitors  
of protein tyrosine phosphatase 1B expression in insulin resistant  
obese non-human mammals by detection of phosphatidylinositol-3-

Cyclins...

B1, gene encoding, as marker; methods for identifying inhibitors of  
protein tyrosine phosphatase 1B expression in insulin resistant obese  
non-human mammals by detection of phosphatidylinositol-3-kinas

Proteins...

B2, complex, gene encoding, as marker; methods for identifying  
inhibitors of protein tyrosine phosphatase 1B expression in insulin  
resistant obese non-human mammals by detection of phosphatidylinosito

Cyclins...

B2, gene encoding, as marker; methods for identifying inhibitors of  
protein tyrosine phosphatase 1B expression in insulin resistant obese  
non-human mammals by detection of phosphatidylinositol-3-kinas

Gene, animal...

c-abl, as marker; methods for identifying inhibitors of protein  
tyrosine phosphatase 1B expression in insulin resistant obese non-human  
mammals by detection of phosphatidylinositol-3-kinase isoforms

Proteins...

c-Cbl-assocd. protein (CAP), gene encoding, as marker; methods for  
identifying inhibitors of protein tyrosine phosphatase 1B expression in  
insulin resistant obese non-human mammals by detection of pho

Gene, animal...

c-fms, as marker; methods for identifying inhibitors of protein  
tyrosine phosphatase 1B expression in insulin resistant obese non-human  
mammals by detection of phosphatidylinositol-3-kinase isoforms

Gene, animal...

c-ros, as marker; methods for identifying inhibitors of protein  
tyrosine phosphatase 1B expression in insulin resistant obese non-human  
mammals by detection of phosphatidylinositol-3-kinase isoforms

Chemokine receptors...

CCR1, gene encoding, as marker; methods for identifying inhibitors of  
protein tyrosine phosphatase 1B expression in insulin resistant obese  
non-human mammals by detection of phosphatidylinositol-3-kin

CD antigens...

CD53, gene encoding, exon 7, as marker; methods for identifying

inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol CD antigens...

CD72, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kin

Proteins...

cofilins, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3

Chemokines...

C10-like, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3

Proteins...

DBI (diazepam binding inhibitor), gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection o

Proteins...

DEXRAS1 (ras-related protein), gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of p

Chaperonins...

DnaJ, testes-specific, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphati

Cyclins...

D2, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinas

Proteins...

E3, retinoic acid inducible, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of pho

Proteins...

FABP (fatty acid-binding protein), gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection

Gene, animal...

Fas, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

Lipids, biological studies...

formation, genes involved in, as markers; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinos

Proteins...

frataxin, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3

Gene, animal...

FSP27, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

Peroxisome proliferator-activated receptors...

$\gamma$ , gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-

Thyrotropin receptors... Talin... Interleukin 1 receptor antagonist...

Profilins... CD44 (antigen)... Entactin... Vimentins... Interleukin 6... gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase is

Gluconeogenesis...



genes involved in, as markers; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase

Gene, animal...  
 Glvr-1, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

Genetic element...  
 GRE (glucocorticosteroid-responsive element), 16, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection

Proteins...  
 GTP-binding, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol

G proteins (guanine nucleotide-binding proteins)...  
 G11, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase

Gene, animal...  
 HAM1, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

Immunoglobulins...  
 heavy chains, VDJ region, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol

Gene, animal...  
 HSL, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

Proteins...  
 human hematopoietic specific protein 1, gene encoding; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol

Proteins...  
 interferon  $\gamma$  inducible protein 47, gene encoding; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol

Proteins...  
 interferon-induced 15 kDa protein, gene encoding, as marker; identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol

Proteins...  
 interferon-induced, 6-16, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol

Proteins...  
 IRS-2 (insulin receptor substrate 2), marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol

Transcription factors...  
 ISGF-7 (interferon-stimulated gene factor 7), gene encoding; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection

Antigens...  
 lymphocyte differentiation, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol

Mannose receptors...  
 macrophage, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol

Drug screening... Adipose tissue... Liver... Mammalia... Mouse... Rat...

Monkey... Chimpanzee... Dog(Canis familiaris)... Cattle... Proteins...  
Organic compounds,biological studies... Polysaccharides,biological studies  
... Oligonucleotides... Polynucleotides... Antisense oligonucleotides...

Antidiabetic agents... Obesity...

methods for identifying inhibitors of protein tyrosine phosphatase 1B  
expression in insulin resistant obese non-human mammals by detection of  
phosphatidylinositol-3-kinase isoforms

Proteins...

mitochondrial matrix protein 1, gene encoding; methods for identifying  
inhibitors of protein tyrosine phosphatase 1B expression in insulin  
resistant obese non-human mammals by detection of phosphatidy

Proteins...

monocyte activating polypeptide 1, gene encoding; methods for  
identifying inhibitors of protein tyrosine phosphatase 1B expression in  
insulin resistant obese non-human mammals by detection of phosphat

Proteins...

Mo54 (mouse protective protein 54), gene encoding, as marker;  
identifying inhibitors of protein tyrosine phosphatase 1B expression in  
insulin resistant obese non-human mammals by detection of phosphat

Gene,animal...

mTRP1, beta variant, as marker; methods for identifying inhibitors of  
protein tyrosine phosphatase 1B expression in insulin resistant obese  
non-human mammals by detection of phosphatidylinositol-3-kin

Proteins...

neuronatin, gene encoding, as marker; methods for identifying  
inhibitors of protein tyrosine phosphatase 1B expression in insulin  
resistant obese non-human mammals by detection of phosphatidylinositol

Diabetes mellitus...

non-insulin-dependent, treatment; methods for identifying inhibitors of  
protein tyrosine phosphatase 1B expression in insulin resistant obese  
non-human mammals by detection of phosphatidylinositol-3-k

Gene,animal...

of gluconeogenesis, as marker; methods for identifying inhibitors of  
protein tyrosine phosphatase 1B expression in insulin resistant obese  
non-human mammals by detection of phosphatidylinositol-3-kina

Gene,animal...

of lipogenesis, as marker; methods for identifying inhibitors of  
protein tyrosine phosphatase 1B expression in insulin resistant obese  
non-human mammals by detection of phosphatidylinositol-3-kinase i

Peptides,biological studies...

oligopeptides; methods for identifying inhibitors of protein tyrosine  
phosphatase 1B expression in insulin resistant obese non-human mammals  
by detection of phosphatidylinositol-3-kinase isoforms

Proteins...

Osteogenesis imperfecta (Ddt), gene encoding, as marker; methods for  
identifying inhibitors of protein tyrosine phosphatase 1B expression in  
insulin resistant obese non-human mammals by detection of p

Proteins...

Ott, gene encoding, as marker; methods for identifying inhibitors of  
protein tyrosine phosphatase 1B expression in insulin resistant obese  
non-human mammals by detection of phosphatidylinositol-3-kina

Transcription factors...

PAN2, gene encoding, as marker; methods for identifying inhibitors of  
protein tyrosine phosphatase 1B expression in insulin resistant obese  
non-human mammals by detection of phosphatidylinositol-3-kin

(etc.)...

CAS REGISTRY NUMBERS:

9024-52-6 A, gene encoding, as marker; methods for identifying inhibitors  
of protein tyrosine phosphatase 1B expression in insulin resistant  
obese non-human mammals by detection of phosphatidylinositol-3-kinase  
isoforms

50-99-7 biological studies, blood, agents for decrease of; methods for  
identifying inhibitors of protein tyrosine phosphatase 1B expression in  
insulin resistant obese non-human mammals by detection of

phosphatidylinositol-3-kinase isoforms

9004-10-8 biological studies, resistance; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

9014-34-0 50812-37-8 9045-77-6 9029-96-3 9004-02-8 9027-95-6 9001-04-1 9075-65-4 9014-19-1 9077-14-9 9013-08-5 9028-47-1 9013-18-7 37213-56-2 140208-23-7 9001-52-9 9001-39-2 162874-99-9 80295-40-5 56941-20-9 37256-73-8 9054-65-3 184111-06-6 9026-39-5 60267-61-0 9047-22-7 9025-26-7 94716-09-3 171715-12-1 141467-20-1 165245-94-3 69106-44-1 9014-43-1 180983-98-6 147014-97-9 156229-84-4 gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

9036-21-9 isoform A, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

9001-60-9 isoform B, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

9000-96-8 liver, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

9004-06-2 metallo-, macrophage, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

300865-11-6 350267-87-7 142243-03-6 methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

9027-13-8 9054-54-0 mitochondrial, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

71965-46-3 80295-33-6 precursor, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

115926-52-8 p50 $\alpha$  and p55 $\alpha$  and p85 $\alpha$  isoforms, markers; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

9002-02-2 9035-42-1 9001-97-2 similar, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

449828-25-5 449828-26-6 449828-27-7 449828-28-8 449828-29-9 449828-30-2 449828-31-3 449828-32-4 449828-33-5 449828-34-6 449828-35-7 449828-36-8 449828-37-9 449834-74-6 unclaimed nucleotide sequence; methods for identifying compds. that inhibit or reduce PTP1B (protein tyrosine phosphatase 1B) expression

9000-83-3 vacuolar, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

37205-61-1 venom basic 1, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

9028-86-8 9027-03-6 2, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms  
9013-02-9 139691-92-2 2, mitochondrial, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms  
9012-42-4 7, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

5/7/9 (Item 4 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2004 American Chemical Society. All rts. reserv.

133280563 CA: 133(20)280563a PATENT  
Human antibodies that bind human IL-12 and methods for producing  
INVENTOR(AUTHOR): Salfeld, Jochen G.; Roguska, Michael; Paskind, Michael; Banerjee, Subhashis; Tracey, Daniel E.; White, Michael; Kaymakcalan, Zehra; Labkovsky, Boris; Sakorafas, Paul; Friedrich, Stuart; Myles, Angela; Veldman, Geertruida M.; Venturini, Amy; Warne, Nicholas W.; Widom, Angela; Elvin, John G.; Duncan, Alexander R.; Derbyshire, Elaine J.; Carmen, Sara; Smith, Stephen; Holtet, Thor Las; Du, Fou Sarah L.

LOCATION: Germany,  
ASSIGNEE: Basf A.-G.; Genetics Institute Inc.; et al.  
PATENT: PCT International ; WO 200056772 A1 DATE: 20000928  
APPLICATION: WO 2000US7946 (20000324) \*US PV126603 (19990325)  
PAGES: 377 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-016/24A; C12N-015/13B; C12N-015/63B; C12N-005/10B; C07K-016/00B; A61K-039/395B; G01N-033/577B; C12P-021/08B; A61P-043/00B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

SECTION:  
CA215003 Immunochemistry  
CA203XXX Biochemical Genetics  
IDENTIFIERS: human antibody interleukin 12 autoimmune disease, inflammation recombinant antibody human interleukin 12

DESCRIPTORS:  
Immunoglobulins...  
A; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases  
Respiratory distress syndrome...  
adult; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases  
Interleukin 2 receptors...  
 $\alpha$ -chain; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases  
Spinal column...  
ankylosing spondylitis; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases  
Transforming growth factors...  
 $\beta$ -; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases  
Interferons...  
 $\beta$ 1,  $\beta$ 1a and  $\beta$ 1b; recombinant human antibodies that bind

human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Phytohemagglutinins...  
blast proliferation assay; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Drug delivery systems...  
carriers; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Antigens...  
CD90; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Fatigue,biological...  
chronic fatigue syndrome; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Immunoglobulins...  
conjugates; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Intestine,disease...  
Crohn's; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Anti-inflammatory agents...  
cytokine; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Immunity...  
disorder, acute and chronic; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Blood coagulation...  
disseminated intravascular; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Immunoglobulins...  
E; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Cytokines...  
EMAP-II or endothelial-monocyte-activating polypeptide II; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Heart,disease...  
failure; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Lung,disease...  
fibrosis; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Immunoglobulins...  
fragments; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Transplant and Transplantation...  
graft-vs.-host reaction; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Immunoglobulins...  
G1; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Immunoglobulins...  
G2; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Immunoglobulins...  
G3; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Immunoglobulins...  
G4; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Immunoglobulins...  
heavy chains; recombinant human antibodies that bind human IL-12 for

treatment of autoimmune diseases and inflammatory diseases

Anemia(disease)...  
hemolytic; recombinant human antibodies that bind human IL-12 for  
treatment of autoimmune diseases and inflammatory diseases

Purpura(disease)...  
Henoch-Schoenlein's; recombinant human antibodies that bind human IL-12  
for treatment of autoimmune diseases and inflammatory diseases

Nervous system...  
Huntington's chorea; recombinant human antibodies that bind human IL-12  
for treatment of autoimmune diseases and inflammatory diseases

Tumor necrosis factor receptors...  
Ig conjugates; recombinant human antibodies that bind human IL-12 for  
treatment of autoimmune diseases and inflammatory diseases

Heart,disease...  
infarction; recombinant human antibodies that bind human IL-12 for  
treatment of autoimmune diseases and inflammatory diseases

Parasite...  
infection; recombinant human antibodies that bind human IL-12 for  
treatment of autoimmune diseases and inflammatory diseases

Cytokines...  
inflammatory, anti-; recombinant human antibodies that bind human IL-12  
for treatment of autoimmune diseases and inflammatory diseases

Intestine,disease...  
inflammatory; recombinant human antibodies that bind human IL-12 for  
treatment of autoimmune diseases and inflammatory diseases

Complement... Signal transduction,biological... Thromboxanes...  
inhibitors; recombinant human antibodies that bind human IL-12 for  
treatment of autoimmune diseases and inflammatory diseases

Drug delivery systems...  
injections, i.v.; recombinant human antibodies that bind human IL-12  
for treatment of autoimmune diseases and inflammatory diseases

Diabetes mellitus...  
insulin-dependent; recombinant human antibodies that bind human IL-12  
for treatment of autoimmune diseases and inflammatory diseases

Baboon... Chimpanzee... Macaca irus... Macaca mulatta... Marmoset...

Primate...  
interleukin 12; recombinant human antibodies that bind human IL-12 for  
treatment of autoimmune diseases and inflammatory diseases

Rheumatoid arthritis...  
juvenile; recombinant human antibodies that bind human IL-12 for  
treatment of autoimmune diseases and inflammatory diseases

Blood vessel,disease...  
Kawasaki; recombinant human antibodies that bind human IL-12 for  
treatment of autoimmune diseases and inflammatory diseases

Immunoglobulins...  
light chains; recombinant human antibodies that bind human IL-12 for  
treatment of autoimmune diseases and inflammatory diseases

Immunoglobulins...  
M; recombinant human antibodies that bind human IL-12 for treatment of  
autoimmune diseases and inflammatory diseases

Antibodies...  
monoclonal; recombinant human antibodies that bind human IL-12 for  
treatment of autoimmune diseases and inflammatory diseases

Spinal cord...  
myelitis, acute transverse; recombinant human antibodies that bind  
human IL-12 for treatment of autoimmune diseases and inflammatory  
diseases

Kidney,disease...  
nephrotic syndrome; recombinant human antibodies that bind human IL-12  
for treatment of autoimmune diseases and inflammatory diseases

Antibodies...  
neutralizing; recombinant human antibodies that bind human IL-12 for  
treatment of autoimmune diseases and inflammatory diseases

Anti-inflammatory agents...

nonsteroidal; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Selectins...

P-, glycoprotein ligand; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Glycoproteins, specific or class...

p-selectin glycoprotein ligand; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Artery, disease...

periarteritis nodosa; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Bioassay...

phytohemagglutinin blast proliferation assay; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Biliary tract...

primary biliary cirrhosis; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

Arthritis...

psoriatic arthritis; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

(etc.)...

# CAS REGISTRY NUMBERS:

80700-82-9 135343-43-0 145001-20-3 148325-41-1 148325-45-5 148325-49-9

156656-32-5 250282-12-3 250282-13-4 250714-30-8 250714-33-1

253143-79-2 269048-31-9 297776-78-4 297776-79-5 297776-80-8

297776-81-9 297776-82-0 297776-83-1 297776-84-2 297776-85-3

297776-86-4 297776-87-5 297776-88-6 297776-89-7 297776-90-0

297776-91-1 297776-92-2 297776-93-3 297776-94-4 297776-95-5

297776-96-6 297776-97-7 297776-98-8 297776-99-9 297777-00-5

297777-01-6 297777-02-7 297777-03-8 297777-04-9 297777-05-0

297777-06-1 297777-07-2 297777-08-3 297777-09-4 297777-10-7

297777-11-8 297777-12-9 297777-13-0 297777-14-1 297777-15-2

297777-16-3 297777-17-4 297777-18-5 297777-19-6 297777-20-9

297777-21-0 297777-22-1 297777-23-2 297777-24-3 297777-25-4

297777-26-5 297777-27-6 297777-28-7 297777-29-8 297777-30-1

297777-31-2 297777-32-3 297777-33-4 297777-34-5 297777-35-6 amino acid sequence; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

28088-64-4D analogs, recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

58-61-7 biological studies, agonists; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

7782-44-7 biological studies, hyperbaric; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

110-86-1D imidazole compds., recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

80449-02-1 142243-02-5 inhibitor; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

9004-06-2 9015-82-1 9025-82-5 9029-60-1 122191-40-6 151769-16-3 inhibitors; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

9036-21-9 IV, inhibitor; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

288-32-4D pyridinyl compds., recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases

50-02-2 50-18-0 50-24-8 50-44-2 59-05-2 83-43-2 89-57-6 443-48-1 446-86-6 504-24-5 599-79-1 4291-63-8 15687-27-1 15722-48-2 51322-75-9 51333-22-3 53123-88-9 62031-54-3 62229-50-9 75706-12-6 79217-60-0 80573-04-2 83869-56-1 104987-11-3 128794-94-5

147245-92-9	159606-08-3	167397-96-8	188596-65-8	260430-71-5		
260430-72-6	297736-18-6	297736-19-7	297736-20-0	297736-21-1		
297736-22-2	297736-23-3	297736-24-4	297738-05-7	297738-06-8		
297738-07-9	297738-08-0	297738-09-1	297738-10-4	297738-11-5		
297738-12-6	297738-13-7	297738-14-8	297738-15-9	297738-16-0		
297738-17-1	297738-18-2	297738-19-3	297738-20-6	297738-21-7		
297738-22-8	297738-23-9	297738-24-0	297738-25-1	297738-26-2		
297738-27-3	297738-28-4	297738-29-5	297738-30-8	297738-31-9		
297738-32-0	297738-33-1	297738-34-2	297738-35-3	297738-36-4		
297738-37-5	297738-38-6	297738-39-7	297738-40-0	297738-41-1		
297738-42-2	297738-43-3	297738-44-4	297738-45-5	297738-46-6		
297738-47-7	297738-48-8	297738-49-9	297738-50-2	297738-51-3		
297738-52-4	297738-53-5	297738-54-6	297738-55-7	297738-56-8		
297738-57-9	297738-58-0	297738-59-1	297738-60-4	297738-61-5		
297738-62-6	297738-63-7	297738-64-8	297738-65-9	297738-66-0		
297738-67-1	297738-68-2	297738-69-3	297738-70-6	297738-71-7		
297738-72-8	297738-73-9	297738-74-0	297738-75-1	297738-76-2		
297738-77-3	297738-78-4	297738-79-5	297738-80-8	297738-81-9		
297738-82-0	297738-83-1	297738-84-2	297738-85-3	297738-86-4		
297738-87-5	297738-88-6	297738-89-7	297738-90-0	297738-91-1		
297738-92-2	297738-93-3	297738-94-4	297738-95-5	297738-96-6		
297738-97-7	297738-98-8	297738-99-9	297739-00-5	297739-01-6		
297739-02-7	297739-03-8	297739-04-9	297739-05-0	297739-06-1		
297739-07-2	297739-08-3	297739-09-4	297739-10-7	297739-11-8		
297739-12-9	297739-13-0	297739-14-1	297739-15-2	297739-16-3		
297739-17-4	297739-18-5	297739-19-6	297739-20-9	297739-21-0		
297739-22-1	297739-23-2	297739-24-3	297739-25-4	297739-26-5		
297739-27-6	297739-28-7	297739-29-8	297739-30-1	297739-31-2		
297739-32-3	297739-33-4	297739-34-5	297739-35-6	297739-36-7		
297739-37-8	297739-38-9	297739-39-0	297739-40-3	297739-41-4		
297739-42-5	297739-43-6	297739-44-7	297739-45-8	297739-46-9		
297739-47-0	297739-48-1	297739-49-2	297739-50-5	297739-51-6		
297739-52-7	297739-53-8	297739-54-9	297739-55-0	297739-56-1		
297739-57-2	297739-58-3	297739-59-4	297739-60-7	297739-61-8		
297739-62-9	297739-63-0	297739-64-1	297739-65-2	297739-66-3		
297739-67-4	297739-68-5	297739-69-6	297739-70-9	297739-71-0		
297739-72-1	297739-73-2	297739-74-3	297739-75-4	297739-76-5		
297739-77-6	297739-78-7	297739-79-8	297739-80-1	297739-81-2		
297739-82-3	297739-83-4	297739-84-5	297739-85-6	297739-86-7		
297739-87-8	297739-88-9	297739-89-0	297739-90-3	297739-91-4		
297739-92-5	297739-93-6	297739-94-7	297739-95-8	297739-96-9		
297739-97-0	297739-98-1	297739-99-2	297740-00-2	297740-01-3		
297740-02-4	297740-03-5	297740-04-6	297740-05-7	297740-06-8		
297740-07-9	297740-08-0	297740-09-1	297740-10-4	297740-11-5		
297740-12-6	297740-13-7	297740-14-8	297740-15-9	297740-16-0		
297740-17-1	297740-18-2	297740-19-3	297740-20-6	297740-21-7		
297740-22-8	297740-23-9	297740-24-0	297740-25-1	297740-26-2		
297740-27-3	297740-28-4	297740-29-5	297740-30-8	297740-31-9		
297740-32-0	297740-33-1	297740-34-2	297740-35-3	297740-36-4		
297740-37-5	297740-38-6	297740-39-7	297740-40-0	297740-41-1		
297740-42-2	297740-43-3	297740-44-4	297740-45-5	297740-46-6		
297740-47-7	297740-48-8	297740-49-9	297740-50-2	297740-51-3		
297740-52-4	297740-53-5	297740-54-6	297740-55-7	297740-56-8		
297740-57-9	297740-58-0	297740-59-1	297740-60-4	297740-61-5		
297740-62-6	297740-63-7	297740-64-8	297740-65-9	297740-66-0		
297740-67-1	297740-68-2	298200-40-5	298200-41-6	298200-42-7		
298200-43-8	298200-44-9	298200-45-0	298200-46-1	298200-47-2		
298200-48-3	298200-49-4	298200-50-7	recombinant human antibodies			
that bind human IL-12 for treatment of autoimmune diseases and						
inflammatory diseases						
226983-90-0	226984-98-1	297782-45-7	297782-46-8	297782-47-9		
297782-48-0	297782-49-1	297782-50-4	297782-51-5	unclaimed		
nucleotide sequence; human antibodies that bind human IL-12 and methods						
for producing						



260430-73-7 297782-22-0 297782-23-1 297782-24-2 297782-25-3  
 297782-26-4 297782-27-5 297782-28-6 297782-29-7 297782-30-0  
 297782-31-1 297782-32-2 297782-33-3 297782-34-4 297782-35-5  
 297782-36-6 297782-37-7 297782-38-8 297782-39-9 297782-40-2  
 297782-41-3 297782-42-4 297782-43-5 297782-44-6 297782-52-6  
 297782-53-7 298200-51-8 298200-52-9 298200-53-0 unclaimed protein  
 sequence; human antibodies that bind human IL-12 and methods for  
 producing  
 297736-25-5 297736-26-6 297736-27-7 297736-28-8 297736-29-9  
 297736-30-2 297736-31-3 297736-32-4 297736-33-5 297736-34-6  
 297736-35-7 297736-36-8 297736-37-9 297736-38-0 297736-39-1  
 297736-40-4 297736-41-5 297736-42-6 297736-43-7 297736-44-8  
 297736-45-9 297736-46-0 297736-47-1 297736-48-2 297736-49-3  
 297736-50-6 297736-51-7 297736-52-8 297736-53-9 297736-54-0  
 297736-55-1 297736-56-2 297736-57-3 297736-58-4 297736-59-5  
 297736-60-8 297736-61-9 297736-62-0 297736-63-1 297736-64-2  
 297736-65-3 297736-66-4 297736-67-5 297736-68-6 297736-69-7  
 297736-70-0 297736-71-1 297736-72-2 297736-73-3 297736-74-4  
 297736-75-5 297736-76-6 297736-77-7 297736-78-8 297736-79-9  
 297736-80-2 297736-81-3 297736-82-4 297736-83-5 297736-84-6  
 297736-85-7 297736-86-8 297736-87-9 297736-88-0 297736-89-1  
 297736-90-4 297736-91-5 297736-92-6 297736-93-7 297736-94-8  
 297736-95-9 297736-96-0 297736-97-1 297736-98-2 297736-99-3  
 297737-00-9 297737-01-0 297737-02-1 297737-03-2 297737-04-3  
 297737-05-4 297737-06-5 297737-07-6 297737-08-7 297737-09-8  
 297737-10-1 297737-11-2 297737-12-3 297737-13-4 297737-14-5  
 297737-15-6 297737-16-7 297737-17-8 297737-18-9 297737-19-0  
 297737-20-3 297737-21-4 297737-22-5 297737-23-6 297737-24-7  
 297737-25-8 297737-26-9 297737-27-0 297737-28-1 297737-29-2  
 297737-30-5 297737-32-7 297737-33-8 297737-34-9 297737-35-0  
 297737-36-1 297737-37-2 297737-38-3 297737-39-4 297737-40-7  
 297737-41-8 297737-42-9 297737-43-0 297737-44-1 297737-45-2  
 297737-46-3 297737-47-4 297737-48-5 297737-49-6 297737-50-9  
 297737-51-0 297737-52-1 297737-53-2 297737-54-3 297737-55-4  
 297737-56-5 297737-57-6 297737-58-7 297737-59-8 297737-60-1  
 297737-61-2 297737-62-3 297737-63-4 297737-64-5 297737-65-6  
 297737-66-7 297737-67-8 297737-68-9 297737-69-0 297737-70-3  
 297737-71-4 297737-72-5 297737-73-6 297737-74-7 297737-75-8  
 297737-76-9 297737-77-0 297737-78-1 297737-79-2 297737-80-5  
 297737-81-6 297737-82-7 297737-83-8 297737-84-9 297737-85-0  
 297737-86-1 297737-87-2 297737-88-3 297737-89-4 297737-90-7  
 297737-91-8 297737-92-9 297737-93-0 297737-94-1 297737-95-2  
 297737-96-3 297737-97-4 297737-98-5 297737-99-6 297738-00-2  
 297738-01-3 297738-02-4 297738-03-5 297738-04-6 unclaimed sequence;  
 human antibodies that bind human IL-12 and methods for producing

5/7/10 (Item 5 from file: 399)  
 DIALOG(R) File 399:CA SEARCH(R)  
 (c) 2004 American Chemical Society. All rts. reserv.

131285285 CA: 131(21)285285e JOURNAL  
 Pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient  
 nonobese diabetic mice  
 AUTHOR(S): Trembleau, Sylvie; Penna, Giuseppe; Gregori, Silvia; Chapman,  
 Harold D.; Serreze, David V.; Magram, Jeanne; Adorini, Luciano  
 LOCATION: Roche Milano Ricerche, Milan, Italy  
 JOURNAL: J. Immunol. DATE: 1999 VOLUME: 163 NUMBER: 5 PAGES:  
 2960-2968 CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English PUBLISHER:  
 American Association of Immunologists  
 SECTION:  
 CA215008 Immunochemistry  
 IDENTIFIERS: diabetes Th1 lymphocyte interleukin 12 deficiency  
 DESCRIPTORS:

Interferons...

γ; lipopolysaccharide-induced, of pancreas-infiltrating CD4+ T cells in wild-type and IL-12-deficient nonobese diabetic mice

T cell(lymphocyte)...

helper cell/inducer, TH1; pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient nonobese diabetic mice

Diabetes mellitus...

insulin-dependent; pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient nonobese diabetic mice

Pancreatic islet of Langerhans...

insulinitis; pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient nonobese diabetic mice

CD4-positive T cell... Interleukin 12... Pancreatic islet of Langerhans...

pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient nonobese diabetic mice

Glycoproteins,specific or class...

PSGL-1 (P-selectin glycoprotein ligand-1); of pancreas-infiltrating CD4+ T cells in wild-type and IL-12-deficient nonobese diabetic mice

? t s5/kwic/9,10

>>>KWIC option is not available in file(s): 399

? ds

Set	Items	Description
S1	33	E1-E3
S2	13	E2-E7
S3	0	S(1 OR S2) AND (PSGL?)
S4	15	(PSGL? OR P(W) SELECTIN(W) GLYCOPROTEIN(W) LIGAND) AND (DIABE- TES)
S5	10	RD S4 (unique items)
? s (psgl? or p(w)selectin(w)glycoprotein(w)ligand)(10n)(antibod?) and (autoimmun? or diabetes)		

1291 PSGL?

4542066 P

33878 SELECTIN

291626 GLYCOPROTEIN

384590 LIGAND

1323 P(W) SELECTIN(W) GLYCOPROTEIN(W) LIGAND

1896131 ANTIBOD?

276 (PSGL? OR

P(W) SELECTIN(W) GLYCOPROTEIN(W) LIGAND) (10N) ANTIBOD?

221473 AUTOIMMUN?

589096 DIABETES

S6 11 (PSGL? OR

P(W) SELECTIN(W) GLYCOPROTEIN(W) LIGAND) (10N) (ANTIBOD?) AND

(AUTOIMMUN? OR DIABETES)

? rd s6

...completed examining records

S7 10 RD S6 (unique items)

? t s7/3/all

7/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0014345912 BIOSIS NO.: 200300303401

CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: A critical role for P-selectin glycoprotein ligand-1.

AUTHOR: Battistini Luca; Piccio Laura; Rossi Barbara; Bach Simona; Galgani Simona; Gasperini Claudio; Ottoboni Linda; Ciabini Donatella; Caramia Maria D; Bernardi Giorgio; Laudanna Carlo; Scarpini Elio; McEver Rodger P ; Butcher Eugene C; Borsellino Giovanna; Constantin Gabriela (Reprint)

AUTHOR ADDRESS: Department of Pathology, Division of General Pathology, University of Verona, Strada le Grazie 8, Verona, 37134, Italy\*\*Italy

AUTHOR E-MAIL ADDRESS: gabriela.constantin@univr.it  
JOURNAL: Blood 101 (12): p4775-4782 June 15, 2003 2003  
MEDIUM: print  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

7/3/2 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2004 Elsevier Science B.V. All rts. reserv.

12182227 EMBASE No: 2003289054  
CD8SUP+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: A critical role for P-selectin glycoprotein ligand-1  
Battistini L.; Piccio L.; Rossi B.; Bach S.; Galgani S.; Gasperini C.; Ottoboni L.; Ciabini D.; Caramia M.D.; Bernardi G.; Laudanna C.; Scarpini E.; McEver R.P.; Butcher E.C.; Borsellino G.; Constantin G.  
G. Constantin, Department of Pathology, Division of General Pathology, University of Verona, Strada le Grazie 8, Verona 37134 Italy  
AUTHOR EMAIL: gabriela.constantin@univr.it  
Blood ( BLOOD ) (United States) 15 JUN 2003, 101/12 (4775-4782)  
CODEN: BLOOA ISSN: 0006-4971  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 46

7/3/3 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2004 American Chemical Society. All rts. reserv.

140092589 CA: 140(7)92589j PATENT  
Antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia  
INVENTOR(AUTHOR): Levanon, Avigdor; Ben-Levy, Rachel; Plaksin, Daniel; Szanton, Esther; Hagai, Yocheved; Hoch, Mar-Chaim Hagit  
LOCATION: USA  
ASSIGNEE: Savient Pharmaceuticals, Inc.  
PATENT: PCT International ; WO 200403166 A2 DATE: 20040108  
APPLICATION: WO 2003US20602 (20030630) \*US 189032 (20020701)  
PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE ; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

7/3/4 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2004 American Chemical Society. All rts. reserv.

140092584 CA: 140(7)92584d PATENT  
Methods for therapeutic treatment utilizing sub-clinical amount of a therapeutic agent combined with or conjugated to an antibody, or fragment thereof

INVENTOR(AUTHOR): Lazarovits, Janette; Nimrod, Abraham; Hoch-Mar-Chaim, Hagit; Levanon, Avigdor

LOCATION: USA

ASSIGNEE: Savient Pharmaceuticals, Inc.

PATENT: PCT International ; WO 200402528 A1 DATE: 20040108

APPLICATION: WO 2003US20604 (20030630) \*US 189025 (20020701)

PAGES: 58 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A; A61K-051/00B; A61K-038/00B; A61K-039/00B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

7/3/5 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

140092576 CA: 140(7)92576c PATENT

Antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation

INVENTOR(AUTHOR): Lazarovits, Janette; Hagay, Yocheved; Plaksin, Daniel; Vogel, Tikva; Nimrod, Abraham; Mar-Ham, Hagit; Szanthon, Ester; Richter, Tamar; Amit, Boaz; Cooperman, Lena; Peretz, Tuvia; Levanon, Avigdor

LOCATION: Israel

PATENT: U.S. Pat. Appl. Publ. ; US 20040002450 A1 DATE: 20040101

APPLICATION: US 32423 (20011231) \*US PV258948 (20001229)

PAGES: 155 pp., Cont.-in-part of U.S. Provisional Ser. No. 258,948.

CODEN: USXXCO LANGUAGE: English CLASS: 514012000; A61K-038/16A; A61K-038/10B; A61K-038/08B; C07K-014/16B; C07K-007/08B; C07K-007/06B

7/3/6 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

140075946 CA: 140(6)75946f PATENT

Multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof

INVENTOR(AUTHOR): Levanon, Avigdor; Hagay, Yocheved; Plaksin, Daniel; Vogel, Tikva; Nimrod, Abraham; Mar-Haim, Hagit; Szanthon, Ester; Richter, Tamar; Amit, Boaz; Cooperman, Lena; Peretz, Tuvia; Lazarovits, Janette

LOCATION: Israel

PATENT: U.S. Pat. Appl. Publ. ; US 20040001839 A1 DATE: 20040101

APPLICATION: US 29988 (20011231) \*US PV258948 (20001229)

PAGES: 149 pp., Cont.-in-part of U.S. Provisional Ser. No. 258,948.

CODEN: USXXCO LANGUAGE: English CLASS: 424178100; A61K-039/395A; C07K-014/46B

7/3/7 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

138152275 CA: 138(11)152275z PATENT

Modulators of P-selectin glycoprotein ligand 1

INVENTOR(AUTHOR): Lin, Rong-Hwa; Wu, Chung-Hsiun; Hsu, Pei-Ling

LOCATION: Taiwan,

ASSIGNEE: Abgenomics Co.  
PATENT: PCT International ; WO 200313603 A1 DATE: 20030220  
APPLICATION: WO 2002US7498 (20020313) \*US PV310196 (20010803) \*US 51497  
(20020118)

PAGES: 44 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A;  
C07K-016/28B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG;  
BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB;  
GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR;  
LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD;  
SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM;  
AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ  
; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;  
IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;  
MR; NE; SN; TD; TG

7/3/8 (Item 6 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2004 American Chemical Society. All rts. reserv.

137108286 CA: 137(8)108286j PATENT  
Antibodies and fragments against epitopes present on cancer, metastatic  
or leukemia cells and platelets for diagnosis and therapy of tumor,  
metastasis, leukemia, autoimmune disease, and inflammation  
INVENTOR(AUTHOR): Lazarovits, Janette; Hagai, Yocheved; Plaksin, Daniel;  
Vogel, Tikva; Nimrod, Abraham; Mar-Haim, Hagit; Szanthon, Ester; Richter,  
Tamar; Amit, Boaz; Kooperman, Lena; Peretz, Tuvia; Levanon, Avigdor  
LOCATION: USA  
ASSIGNEE: Bio-Technology General Corp.  
PATENT: PCT International ; WO 200253700 A2 DATE: 20020711  
APPLICATION: WO 2001US49442 (20011231) \*US 751181 (20001229) \*US PV258948  
(20001229)

PAGES: 310 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;  
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZM; ZW; AM;  
AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ  
; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;  
IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;  
MR; NE; SN; TD; TG

7/3/9 (Item 7 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2004 American Chemical Society. All rts. reserv.

133280563 CA: 133(20)280563a PATENT  
Human antibodies that bind human IL-12 and methods for producing  
INVENTOR(AUTHOR): Salfeld, Jochen G.; Roguska, Michael; Paskind, Michael;  
Banerjee, Subhashis; Tracey, Daniel E.; White, Michael; Kaymakcalan, Zehra;  
Labkovsky, Boris; Sakorafas, Paul; Friedrich, Stuart; Myles, Angela;  
Veldman, Geertruida M.; Venturini, Amy; Warne, Nicholas W.; Widom, Angela;  
Elvin, John G.; Duncan, Alexander R.; Derbyshire, Elaine J.; Carmen, Sara;  
Smith, Stephen; Holtet, Thor Las; Du, Fou Sarah L.  
LOCATION: Germany,  
ASSIGNEE: Basf A.-G.; Genetics Institute Inc.; et al.  
PATENT: PCT International ; WO 200056772 A1 DATE: 20000928  
APPLICATION: WO 2000US7946 (20000324) \*US PV126603 (19990325)  
PAGES: 377 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-016/24A;  
C12N-015/13B; C12N-015/63B; C12N-005/10B; C07K-016/00B; A61K-039/395B;  
G01N-033/577B; C12P-021/08B; A61P-043/00B DESIGNATED COUNTRIES: AE; AG; AL  
; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM;

DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP;  
 KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL;  
 PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN;  
 YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM  
 ; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR;  
 GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML;  
 MR; NE; SN; TD; TG

7/3/10 (Item 8 from file: 399)  
 DIALOG(R)File 399:CA SEARCH(R)  
 (c) 2004 American Chemical Society. All rts. reserv.

132303492 CA: 132(23)303492x PATENT  
 Inhibition of differentiation of T-cells to cytotoxic lymphocytes by  
 P-selectin ligand (PSGL) antagonists  
 INVENTOR(AUTHOR): Manjunath, Narasimhaswamy; Hans Von Andrian, Ulrich  
 LOCATION: USA  
 ASSIGNEE: Genetics Institute, Inc.; CBR Laboratories, Inc.  
 PATENT: PCT International ; WO 200025808 A1 DATE: 20000511  
 APPLICATION: WO 99US25501 (19991029) \*US PV106315 (19981030)  
 PAGES: 66 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-038/16A;  
 A61K-038/17B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY;  
 CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL;  
 IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN;  
 MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA;  
 UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM  
 DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE;  
 CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF;  
 CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG  
 ? ds

Set	Items	Description
S1	33	E1-E3
S2	13	E2-E7
S3	0	S(1 OR S2) AND (PSGL?)
S4	15	(PSGL? OR P(W) SELECTIN(W) GLYCOPROTEIN(W) LIGAND) AND (DIABE- TES)
S5	10	RD S4 (unique items)
S6	11	(PSGL? OR P(W) SELECTIN(W) GLYCOPROTEIN(W) LIGAND) (10N) (ANTIB- OD?) AND (AUTOIMMUN? OR DIABETES)
S7	10	RD S6 (unique items)
? s (psgl? or p(w) selectin(w) glycoprotein(w) ligand) (10n) (antibod?) and (apoptosis)		
	1291	PSGL?
	4542066	P
	33878	SELECTIN
	291626	GLYCOPROTEIN
	384590	LIGAND
	1323	P(W) SELECTIN(W) GLYCOPROTEIN(W) LIGAND
	1896131	ANTIBOD?
	276	(PSGL? OR P(W) SELECTIN(W) GLYCOPROTEIN(W) LIGAND) (10N) ANTIBOD?
	323263	APOPTOSIS
S8	6	(PSGL? OR P(W) SELECTIN(W) GLYCOPROTEIN(W) LIGAND) (10N) (ANTIBOD?) AND (APOPTOSIS)
? rd s8		
...completed examining records		
	S9	5 RD S8 (unique items)
? t s9/3/all		

9/3/1 (Item 1 from file: 5)  
 DIALOG(R)File 5:Biosis Previews(R)  
 (c) 2004 BIOSIS. All rts. reserv.

0013667939 BIOSIS NO.: 200200261450

Adhesion to E-selectin promotes growth inhibition and **apoptosis** of human and murine hematopoietic progenitor cells

AUTHOR: Winkler Ingrid G (Reprint); Eto Tetsuya (Reprint); Purton Louise E (Reprint); Haylock David N (Reprint); Snapp Karen R; Kansas Geoffrey S; Simmons Paul J (Reprint); Levesque Jean-Pierre (Reprint)

AUTHOR ADDRESS: Stem Cell Biology Laboratory, Peter MacCallum Cancer Institute, Melbourne, VIC, Australia\*\*Australia

JOURNAL: Blood 98 (11 Part 1): p797a November 16, 2001 2001

MEDIUM: print

CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

9/3/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0012251034 BIOSIS NO.: 199900510694

PSGL-1-mediated adhesion of human hematopoietic progenitors to P-selectin results in suppression of hematopoiesis

AUTHOR: Levesque Jean-Pierre; Zannettino Andrew C W; Pudney Melanie; Niutta Silvana; Haylock David N; Snapp Karen R; Kansas Geoffrey S; Berndt Michael C; Simmons Paul J (Reprint)

AUTHOR ADDRESS: Hanson Centre for Cancer Research, Matthew Roberts Laboratory, Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, SA, 5000, Australia\*\*Australia

JOURNAL: Immunity 11 (3): p369-378 Sept., 1999 1999

MEDIUM: print

ISSN: 1074-7613

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

9/3/3 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

140092589 CA: 140(7)92589j PATENT

Antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

INVENTOR(AUTHOR): Levanon, Avigdor; Ben-Levy, Rachel; Plaksin, Daniel; Szanton, Esther; Hagai, Yocheved; Hoch, Mar-Chaim Hagit

LOCATION: USA

ASSIGNEE: Savient Pharmaceuticals, Inc.

PATENT: PCT International ; WO 200403166 A2 DATE: 20040108

APPLICATION: WO 2003US20602 (20030630) \*US 189032 (20020701)

PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE ; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;

BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

9/3/4 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2004 American Chemical Society. All rts. reserv.

140092576 CA: 140(7)92576c PATENT  
Antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation  
INVENTOR(AUTHOR): Lazarovits, Janette; Hagay, Yocheved; Plaksin, Daniel; Vogel, Tikva; Nimrod, Abraham; Mar-Ham, Hagit; Szanthon, Ester; Richter, Tamar; Amit, Boaz; Cooperman, Lena; Peretz, Tuvia; Levanon, Avigdor  
LOCATION: Israel  
PATENT: U.S. Pat. Appl. Publ. ; US 20040002450 A1 DATE: 20040101  
APPLICATION: US 32423 (20011231) \*US PV258948 (20001229)  
PAGES: 155 pp., Cont.-in-part of U.S. Provisional Ser. No. 258,948.  
CODEN: USXXCO LANGUAGE: English CLASS: 514012000; A61K-038/16A; A61K-038/10B; A61K-038/08B; C07K-014/16B; C07K-007/08B; C07K-007/06B

9/3/5 (Item 3 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2004 American Chemical Society. All rts. reserv.

138152275 CA: 138(11)152275z PATENT  
Modulators of P-selectin glycoprotein ligand 1  
INVENTOR(AUTHOR): Lin, Rong-Hwa; Wu, Chung-Hsiun; Hsu, Pei-Ling  
LOCATION: Taiwan,  
ASSIGNEE: Abgenomics Co.  
PATENT: PCT International ; WO 200313603 A1 DATE: 20030220  
APPLICATION: WO 2002US7498 (20020313) \*US PV310196 (20010803) \*US 51497 (20020118)  
PAGES: 44 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A; C07K-016/28B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG  
? ds

Set	Items	Description
S1	33	E1-E3
S2	13	E2-E7
S3	0	S(1 OR S2) AND (PSGL?)
S4	15	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) AND (DIABETES)
S5	10	RD S4 (unique items)
S6	11	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) (10N) (ANTIBOD?) AND (AUTOIMMUN? OR DIABETES)
S7	10	RD S6 (unique items)
S8	6	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) (10N) (ANTIBOD?) AND (APOPTOSIS)
S9	5	RD S8 (unique items)

? s (psgl? or p(w)selectin(w)glycoprotein(w)ligand) (10n) (antibod?) and (t(w)cell? or t(w)lymphocyt? or nk or natural(w)killer)  
Processing  
Processing  
Processing



Processing  
Processing

1291 PSGL?  
4542066 P  
33878 SELECTIN  
291626 GLYCOPROTEIN  
384590 LIGAND  
1323 P(W) SELECTIN(W) GLYCOPROTEIN(W) LIGAND  
1896131 ANTIBOD?  
276 (PSGL? OR  
P(W) SELECTIN(W) GLYCOPROTEIN(W) LIGAND) (10N) ANTIBOD?  
4812141 T  
10596180 CELL?  
621976 T(W) CELL?  
4812141 T  
1184902 LYMPHOCYT?  
439095 T(W) LYMPHOCYT?  
69730 NK  
1034538 NATURAL  
119554 KILLER  
89342 NATURAL(W) KILLER  
S10 42 (PSGL? OR  
P(W) SELECTIN(W) GLYCOPROTEIN(W) LIGAND) (10N) (ANTIBOD?) AND  
(T(W) CELL? OR T(W) LYMPHOCYT? OR NK OR NATURAL(W) KILLER)

? rd s10

...completed examining records

S11 20 RD S10 (unique items)

? s s11 and apoptosis

20 S11

323263 APOPTOSIS

S12 2 S11 AND APOPTOSIS

? t s12/3/all

12/3/1 (Item 1 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

140092589 CA: 140(7)92589j PATENT

Antibodies or scFv fragments specific to PSGL-1 epitopes useful for  
diagnosis, prognosis and treatment of cancer, inflammation, infection,  
autoimmune disease, metastasis and leukemia

INVENTOR(AUTHOR): Levanon, Avigdor; Ben-Levy, Rachel; Plaksin, Daniel;  
Szanton, Esther; Hagai, Yocheved; Hoch, Mar-Chaim Hagit

LOCATION: USA

ASSIGNEE: Savient Pharmaceuticals, Inc.

PATENT: PCT International ; WO 200403166 A2 DATE: 20040108

APPLICATION: WO 2003US20602 (20030630) \*US 189032 (20020701)

PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC;  
SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA;  
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE  
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;  
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;  
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

12/3/2 (Item 2 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

138152275 CA: 138(11)152275z PATENT

Modulators of P-selectin glycoprotein ligand 1

INVENTOR(AUTHOR): Lin, Rong-Hwa; Wu, Chung-Hsiun; Hsu, Pei-Ling

LOCATION: Taiwan,

ASSIGNEE: Abgenomics Co.

PATENT: PCT International ; WO 200313603 A1 DATE: 20030220

APPLICATION: WO 2002US7498 (20020313) \*US PV310196 (20010803) \*US 51497 (20020118)

PAGES: 44 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A;  
C07K-016/28B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG;  
BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB;  
GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR;  
LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD;  
SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM;  
AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ  
; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;  
IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;  
MR; NE; SN; TD; TG  
? ds

Set	Items	Description
S1	33	E1-E3
S2	13	E2-E7
S3	0	S(1 OR S2) AND (PSGL?)
S4	15	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) AND (DIABETES)
S5	10	RD S4 (unique items)
S6	11	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) (10N) (ANTIBOD?) AND (AUTOIMMUN? OR DIABETES)
S7	10	RD S6 (unique items)
S8	6	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) (10N) (ANTIBOD?) AND (APOPTOSIS)
S9	5	RD S8 (unique items)
S10	42	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) (10N) (ANTIBOD?) AND (T(W)CELL? OR T(W)LYMPHOCYT? OR NK OR NATURAL(W)KILLER)
S11	20	RD S10 (unique items)
S12	2	S11 AND APOPTOSIS

? t s11/3/all

11/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0014396997 BIOSIS NO.: 200300355716

The role of selectins in inflammation and disease.

AUTHOR: Ley Klaus (Reprint)

AUTHOR ADDRESS: Cardiovascular Research Center and Departments of  
Biomedical Engineering, Molecular Physiology and Biological Physics,  
University of Virginia, MR5 Building, Room 1013, PO Box 801394,  
Charlottesville, VA, 22908-1394, USA\*\*USA

AUTHOR E-MAIL ADDRESS: klausley@virginia.edu

JOURNAL: Trends in Molecular Medicine 9 (6): p263-268 June 2003 2003

MEDIUM: print

ISSN: 1471-4914 (ISSN print)

DOCUMENT TYPE: Article; Literature Review

RECORD TYPE: Abstract

LANGUAGE: English

11/3/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0014345912 BIOSIS NO.: 200300303401

CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: A critical role for P-selectin glycoprotein ligand-1.  
AUTHOR: Battistini Luca; Piccio Laura; Rossi Barbara; Bach Simona; Galgani Simona; Gasperini Claudio; Ottoboni Linda; Ciabini Donatella; Caramia Maria D; Bernardi Giorgio; Laudanna Carlo; Scarpini Elio; McEver Rodger P ; Butcher Eugene C; Borsellino Giovanna; Constantin Gabriela (Reprint)  
AUTHOR ADDRESS: Department of Pathology, Division of General Pathology, University of Verona, Strada le Grazie 8, Verona, 37134, Italy\*\*Italy  
AUTHOR E-MAIL ADDRESS: gabriela.constantin@univr.it  
JOURNAL: Blood 101 (12): p4775-4782 June 15, 2003 2003  
MEDIUM: print  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

11/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0014116452 BIOSIS NO.: 200300075171  
Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: Implications in modulating lymphocyte migration to skin.  
AUTHOR: Dimitroff Charles J; Bernacki Ralph J; Sackstein Robert (Reprint)  
AUTHOR ADDRESS: Harvard Institutes of Medicine, 77 Ave Louis Pasteur, Room 671, Boston, MA, 02115, USA\*\*USA  
AUTHOR E-MAIL ADDRESS: rsackstein@rics.bwh.harvard.edu  
JOURNAL: Blood 101 (2): p602-610 January 15, 2003 2003  
MEDIUM: print  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

11/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0014080818 BIOSIS NO.: 200300049537  
Characterisation of adhesion receptors mediating lymphocyte adhesion to bronchial endothelium provides evidence for a distinct lung homing pathway.  
AUTHOR: Ainslie M P; McNulty C A; Huynh T; Symon F A; Wardlaw A J (Reprint)  
AUTHOR ADDRESS: Department of Respiratory Medicine, Glenfield Hospital, Groby Road, Leicester, LE3 9QP, UK\*\*UK  
AUTHOR E-MAIL ADDRESS: aw24@le.ac.uk  
JOURNAL: Thorax 57 (12): p1054-1059 December 2002 2002  
MEDIUM: print  
ISSN: 0040-6376  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

11/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0013396971 BIOSIS NO.: 200100568810  
Tonsillar B cells do not express PSGL-1, but a significant fraction

displays the cutaneous lymphocyte antigen and exhibits effective E- and P-selectin ligand activity  
AUTHOR: Armerding Dieter (Reprint); Fuhlbrigge Robert C; Kieffer J David; Kupper Thomas S  
AUTHOR ADDRESS: Donaustrasse 73, A-3421, Hoefflein an der Donau, Austria\*\* Austria  
JOURNAL: International Archives of Allergy and Immunology 126 (1): p78-90 September, 2001 2001  
MEDIUM: print  
ISSN: 1018-2438  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

11/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0012890151 BIOSIS NO.: 200100061990  
P-selectin glycoprotein ligand 1 (PSGL-1) is a physiological ligand for E-selectin in mediating T helper 1 lymphocyte migration  
AUTHOR: Hirata Takako; Merrill-Skoloff Glenn; Aab Melissa; Yang Jing; Furie Barbara C; Furie Bruce (Reprint)  
AUTHOR ADDRESS: Beth Israel Deaconess Medical Center, Research East No. 319, Boston, MA, 02215, USA\*\*USA  
JOURNAL: Journal of Experimental Medicine 192 (11): p1669-1675 December 4, 2000 2000  
MEDIUM: print  
ISSN: 0022-1007  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

11/3/7 (Item 7 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0011960242 BIOSIS NO.: 199900219902  
P- and L-selectin mediate binding of T cells to chronically inflamed human airway endothelium  
AUTHOR: Symon Fiona A; McNulty Clare A; Wardlaw Andrew J (Reprint)  
AUTHOR ADDRESS: Respiratory Medicine, Glenfield Hospital, Groby Road, Leicester, LE3 9QP, UK\*\*UK  
JOURNAL: European Journal of Immunology 29 (4): p1324-1333 April, 1999 1999  
MEDIUM: print  
ISSN: 0014-2980  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

11/3/8 (Item 8 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0011473259 BIOSIS NO.: 199800267506  
Adhesion of monocytes to vascular cell adhesion molecule-1-transduced human endothelial cells. Implications for atherogenesis  
AUTHOR: Gerszten Robert E; Lim Yaw-Chyn; Ding Han T; Snapp Karen; Kansas Goeffrey; Dichek David A; Cabanas Carlos; Sanchez-Madrid Francisco; Gimbrone Michael A Jr; Rosenzweig Anthony; Luscinskas Francis W (Reprint)

AUTHOR ADDRESS: Vascular Res. Div., Brigham and Women's Hosp., 221 Longwood  
Avenue, Boston, MA 02115, USA\*\*USA  
JOURNAL: Circulation Research 82 (8): p871-878 May 4, 1998 1998  
MEDIUM: print  
ISSN: 0009-7330  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

11/3/9 (Item 9 from file: 5)  
DIALOG(R)File 5: Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0011277514 BIOSIS NO.: 199800071761  
A novel **P-selectin glycoprotein ligand-1** monoclonal  
**antibody** recognizes an epitope within the tyrosine sulfate motif of  
human **PSGL-1** and blocks recognition of both P- and L-selectin  
AUTHOR: Snapp Karen R; Ding Han; Atkins Kristin; Warnke Roger; Luscinskas  
Francis W; Kansas Geoffrey S (Reprint)  
AUTHOR ADDRESS: Dep. Microbiol.-Immunol., Northwestern Med. Sch., 303 E.  
Chicago Ave., Chicago, IL 60611, USA\*\*USA  
JOURNAL: Blood 91 (1): p154-164 Jan. 1, 1998 1998  
MEDIUM: print  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

11/3/10 (Item 10 from file: 5)  
DIALOG(R)File 5: Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0011212160 BIOSIS NO.: 199800006407  
The binding of **T cell-expressed P-selectin glycoprotein**  
**ligand-1** to E- and P-selectin is differentially regulated  
AUTHOR: Borges Eric; Pendl Gunther; Eytner Ruth; Steegmaier Martin;  
Zoellner Olaf; Vestweber Dietmar (Reprint)  
AUTHOR ADDRESS: Inst. Cell Biol., ZMBE, Technol., Mendelstr. 11, D-48149  
Muenster, Germany\*\*Germany  
JOURNAL: Journal of Biological Chemistry 272 (45): p28786-28792 Nov. 7,  
1997 1997  
MEDIUM: print  
ISSN: 0021-9258  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

11/3/11 (Item 11 from file: 5)  
DIALOG(R)File 5: Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0010614730 BIOSIS NO.: 199699248790  
**P-selectin glycoprotein ligand-1** is broadly expressed in cells of myeloid,  
lymphoid, and dendritic lineage and in some nonhematopoietic cells  
AUTHOR: Laszik Zoltan; Jansen Paul J; Cummings Richard D; Tedder Thomas F;  
McEver Rodger P; Moore Kevin L (Reprint)  
AUTHOR ADDRESS: University Oklahoma Health Sci. Cent., 825 NE 13th St.,  
Oklahoma City, OK 73104-5073, USA\*\*USA  
JOURNAL: Blood 88 (8): p3010-3021 1996 1996  
ISSN: 0006-4971  
DOCUMENT TYPE: Article

RECORD TYPE: Abstract  
LANGUAGE: English

11/3/12 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2004 Elsevier Science B.V. All rts. reserv.

12190362 EMBASE No: 2003293119  
P-selectin enhances generation of CD14SUP+ CD16SUP+ dendritic-like cells and inhibits macrophage maturation from human peripheral blood monocytes  
Li G.; Kim Y.-J.; Mantel C.; Broxmeyer H.E.  
Dr. H.E. Broxmeyer, Walther Oncology Center, Indiana Univ. School of Medicine, Building R4, 1044 West Walnut Street, Indianapolis, IN 46202-5254 United States  
AUTHOR EMAIL: hbroxmey@iupui.edu  
Journal of Immunology ( J. IMMUNOL. ) (United States) 15 JUL 2003, 171/2 (669-677)  
CODEN: JOIMA ISSN: 0022-1767  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 62

11/3/13 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2004 Elsevier Science B.V. All rts. reserv.

12182227 EMBASE No: 2003289054  
CD8SUP+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: A critical role for P-selectin glycoprotein ligand-1  
Battistini L.; Piccio L.; Rossi B.; Bach S.; Galgani S.; Gasperini C.; Ottoboni L.; Ciabini D.; Caramia M.D.; Bernardi G.; Laudanna C.; Scarpini E.; McEver R.P.; Butcher E.C.; Borsellino G.; Constantin G.  
G. Constantin, Department of Pathology, Division of General Pathology, University of Verona, Strada le Grazie 8, Verona 37134 Italy  
AUTHOR EMAIL: gabriela.constantin@univr.it  
Blood ( BLOOD ) (United States) 15 JUN 2003, 101/12 (4775-4782)  
CODEN: BLOOA ISSN: 0006-4971  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 46

11/3/14 (Item 3 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2004 Elsevier Science B.V. All rts. reserv.

11799410 EMBASE No: 2002370886  
P-, E-, and L-selectin mediate migration of activated CD8SUP+ T lymphocytes into inflamed skin  
Hirata T.; Furie B.C.; Furie B.  
Dr. B. Furie, Research East #319, Beth Israel Deaconess Medical Center, P.O. Box 15732, Boston, MA 02215 United States  
AUTHOR EMAIL: bfurie@caregroup.harvard.edu  
Journal of Immunology ( J. IMMUNOL. ) (United States) 15 OCT 2002, 169/8 (4307-4313)  
CODEN: JOIMA ISSN: 0022-1767  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 44

11/3/15 (Item 4 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2004 Elsevier Science B.V. All rts. reserv.

11348541 EMBASE No: 2001361410  
IL-12, STAT4-dependent up-regulation of CD4SUP+ T cell core 2  
beta-1,6-n-acetylglucosaminyltransferase, an enzyme essential for  
biosynthesis of P-selectin ligandsSUP1  
Lim Y.; Xie H.; Come C.E.; Alexander S.I.; Grusby M.J.; Lichtman A.H.;  
Luscinskas F.W.  
Dr. F.W. Luscinskas, Brigham and Women's Hospital, 221 Longwood Avenue,  
Boston, MA 02115 United States  
AUTHOR EMAIL: fluscinskas@rics.bwh.harvard.edu  
Journal of Immunology ( J. IMMUNOL. ) (United States) 15 OCT 2001,  
167/8 (4476-4484)  
CODEN: JOIMA ISSN: 0022-1767  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 51

11/3/16 (Item 5 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2004 Elsevier Science B.V. All rts. reserv.

06773101 EMBASE No: 1997054594  
P-selectin glycoprotein ligand-1 (PSGL-1) on T helper 1 but not on T  
helper 2 cells binds to P-selectin and supports migration into inflamed  
skin  
Borges E.; Tietz W.; Steegmaier M.; Moll T.; Hallmann R.; Hamann A.;  
Vestweber D.  
D. Vestweber, Institute of Cell Biology, ZMBE Technologiehof, Mendelstr.  
11, D-48149 Munster Germany  
Journal of Experimental Medicine ( J. EXP. MED. ) (United States) 1997,  
185/3 (573-578)  
CODEN: JEMEA ISSN: 0022-1007  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 35

11/3/17 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2004 American Chemical Society. All rts. reserv.

140092589 CA: 140(7)92589j PATENT  
Antibodies or scFv fragments specific to PSGL-1 epitopes useful for  
diagnosis, prognosis and treatment of cancer, inflammation, infection,  
autoimmune disease, metastasis and leukemia  
INVENTOR(AUTHOR): Levanon, Avigdor; Ben-Levy, Rachel; Plaksin, Daniel;  
Szanton, Esther; Hagai, Yocheved; Hoch, Mar-Chaim Hagit  
LOCATION: USA  
ASSIGNEE: Savient Pharmaceuticals, Inc.  
PATENT: PCT International ; WO 200403166 A2 DATE: 20040108  
APPLICATION: WO 2003US20602 (20030630) \*US 189032 (20020701)  
PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC;  
SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA;  
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE  
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;  
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;

BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

11/3/18 (Item 2 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

138152275 CA: 138(11)152275z PATENT  
Modulators of P-selectin glycoprotein ligand 1  
INVENTOR(AUTHOR): Lin, Rong-Hwa; Wu, Chung-Hsiun; Hsu, Pei-Ling  
LOCATION: Taiwan,  
ASSIGNEE: Abgenomics Co.  
PATENT: PCT International ; WO 200313603 A1 DATE: 20030220  
APPLICATION: WO 2002US7498 (20020313) \*US PV310196 (20010803) \*US 51497  
(20020118)

PAGES: 44 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A;  
C07K-016/28B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG;  
BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB;  
GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR;  
LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD;  
SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM;  
AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ;  
; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;  
IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;  
MR; NE; SN; TD; TG

11/3/19 (Item 3 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

133280563 CA: 133(20)280563a PATENT  
Human antibodies that bind human IL-12 and methods for producing  
INVENTOR(AUTHOR): Salfeld, Jochen G.; Roguska, Michael; Paskind, Michael;  
Banerjee, Subhashis; Tracey, Daniel E.; White, Michael; Kaymakcalan, Zehra;  
Labkovsky, Boris; Sakorafas, Paul; Friedrich, Stuart; Myles, Angela;  
Veldman, Geertruida M.; Venturini, Amy; Warne, Nicholas W.; Widom, Angela;  
Elvin, John G.; Duncan, Alexander R.; Derbyshire, Elaine J.; Carmen, Sara;  
Smith, Stephen; Holtet, Thor Las; Du, Fou Sarah L.

LOCATION: Germany,  
ASSIGNEE: Basf A.-G.; Genetics Institute Inc.; et al.  
PATENT: PCT International ; WO 200056772 A1 DATE: 20000928  
APPLICATION: WO 2000US7946 (20000324) \*US PV126603 (19990325)  
PAGES: 377 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-016/24A;  
C12N-015/13B; C12N-015/63B; C12N-005/10B; C07K-016/00B; A61K-039/395B;  
G01N-033/577B; C12P-021/08B; A61P-043/00B DESIGNATED COUNTRIES: AE; AG; AL;  
; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM;  
DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP;  
KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL;  
PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN;  
YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM;  
; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR;  
GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML;  
MR; NE; SN; TD; TG

11/3/20 (Item 4 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2004 American Chemical Society. All rts. reserv.

132303492 CA: 132(23)303492x PATENT  
Inhibition of differentiation of T-cells to cytotoxic lymphocytes by  
P-selectin ligand (PSGL) antagonists  
INVENTOR(AUTHOR): Manjunath, Narasimhaswamy; Hans Von Andrian, Ulrich



LOCATION: USA

ASSIGNEE: Genetics Institute, Inc.; CBR Laboratories, Inc.

PATENT: PCT International ; WO 200025808 A1 DATE: 20000511

APPLICATION: WO 99US25501 (19991029) \*US PV106315 (19981030)

PAGES: 66 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-038/16A;

A61K-038/17B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

?

PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES

? ds

Set	Items	Description
S1	33	E1-E3
S2	13	E2-E7
S3	0	S(1 OR S2) AND (PSGL?)
S4	15	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) AND (DIABETES)
S5	10	RD S4 (unique items)
S6	11	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) (10N) (ANTIBOD?) AND (AUTOIMMUN? OR DIABETES)
S7	10	RD S6 (unique items)
S8	6	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) (10N) (ANTIBOD?) AND (APOPTOSIS)
S9	5	RD S8 (unique items)
S10	42	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) (10N) (ANTIBOD?) AND (T(W)CELL? OR T(W)LYMPHOCYT? OR NK OR NATURAL(W)KILLER)
S11	20	RD S10 (unique items)
S12	2	S11 AND APOPTOSIS
?		